Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Buy
67
TGTX Quote, Financials, Valuation and Earnings
Last price:
$41.87
Seasonality move
:
15.93%
Day range:
$41.43 - $43.03
52-week range:
$12.93 - $43.03
Dividend yield:
0%
P/E ratio:
299.21x
P/S ratio:
19.95x
P/B ratio:
29.59x
Volume:
2.2M
Avg. volume:
2.8M
1-year change:
172.54%
Market cap:
$6.6B
Revenue:
$329M
EPS (TTM):
$0.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$100.7M | $0.20 | 84.44% | -95.36% | $42.83 |
|
ADMA
ADMA Biologics
|
$112.8M | $0.15 | 42.17% | 75% | $25.27 |
|
CARA
Cara Therapeutics
|
$1.6M | -$2.94 | -73.37% | -83.05% | $12.00 |
|
EDIT
Editas Medicine
|
$37.2M | -$0.33 | -23.05% | -22.53% | $3.75 |
|
OCGN
Ocugen
|
$300K | -$0.05 | -100% | -- | $6.75 |
|
OCUL
Ocular Therapeutix
|
$16.9M | -$0.22 | 16.58% | -42.86% | $17.45 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$41.89 | $42.83 | $6.6B | 299.21x | $0.00 | 0% | 19.95x |
|
ADMA
ADMA Biologics
|
$19.65 | $25.27 | $4.7B | 23.96x | $0.00 | 0% | 11.19x |
|
CARA
Cara Therapeutics
|
$5.15 | $12.00 | $23.6M | -- | $0.00 | 0% | 3.29x |
|
EDIT
Editas Medicine
|
$1.37 | $3.75 | $113.7M | -- | $0.00 | 0% | 3.49x |
|
OCGN
Ocugen
|
$0.58 | $6.75 | $168.2M | -- | $0.00 | 0% | 38.49x |
|
OCUL
Ocular Therapeutix
|
$7.44 | $17.45 | $1.2B | -- | $0.00 | 0% | 18.47x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
52.36% | 3.612 | 5.21% | 4.85x |
|
ADMA
ADMA Biologics
|
17.17% | 4.789 | 1.78% | 2.76x |
|
CARA
Cara Therapeutics
|
-- | -3.732 | -- | 10.67x |
|
EDIT
Editas Medicine
|
-- | 0.335 | -- | 3.71x |
|
OCGN
Ocugen
|
49.18% | 4.395 | 12.22% | 2.71x |
|
OCUL
Ocular Therapeutix
|
17.85% | 3.384 | 5.09% | 10.26x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$92.8M | $29.9M | 6.86% | 12.81% | 30.05% | -$25.7M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
CARA
Cara Therapeutics
|
$1.5M | -$5.5M | -374.56% | -374.56% | -374.98% | -$4M |
|
EDIT
Editas Medicine
|
-- | -$34.4M | -100% | -100% | -112.28% | -$51.3M |
|
OCGN
Ocugen
|
-- | -$13.8M | -136.46% | -171.04% | -1811.52% | -$10.4M |
|
OCUL
Ocular Therapeutix
|
$15.9M | -$50.6M | -51.22% | -62.66% | -265.09% | -$39.6M |
TG Therapeutics vs. Competitors
-
Which has Higher Returns TGTX or ADMA?
ADMA Biologics has a net margin of 21.57% compared to TG Therapeutics's net margin of 95.19%. TG Therapeutics's return on equity of 12.81% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About TGTX or ADMA?
TG Therapeutics has a consensus price target of $42.83, signalling upside risk potential of 2.25%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 28.61%. Given that ADMA Biologics has higher upside potential than TG Therapeutics, analysts believe ADMA Biologics is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 ADMAADMA Biologics4 0 0 -
Is TGTX or ADMA More Risky?
TG Therapeutics has a beta of 2.303, which suggesting that the stock is 130.31% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.
-
Which is a Better Dividend Stock TGTX or ADMA?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or ADMA?
TG Therapeutics quarterly revenues are $108.2M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. TG Therapeutics's net income of $23.3M is lower than ADMA Biologics's net income of $111.9M. Notably, TG Therapeutics's price-to-earnings ratio is 299.21x while ADMA Biologics's PE ratio is 23.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 19.95x versus 11.19x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics19.95x 299.21x $108.2M $23.3M ADMAADMA Biologics11.19x 23.96x $117.5M $111.9M
-
Which has Higher Returns TGTX or CARA?
Cara Therapeutics has a net margin of 21.57% compared to TG Therapeutics's net margin of -527.77%. TG Therapeutics's return on equity of 12.81% beat Cara Therapeutics's return on equity of -374.56%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M CARACara Therapeutics70.96% -$1.73 -$4.6M -
What do Analysts Say About TGTX or CARA?
TG Therapeutics has a consensus price target of $42.83, signalling upside risk potential of 2.25%. On the other hand Cara Therapeutics has an analysts' consensus of $12.00 which suggests that it could grow by 133.01%. Given that Cara Therapeutics has higher upside potential than TG Therapeutics, analysts believe Cara Therapeutics is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 CARACara Therapeutics0 1 0 -
Is TGTX or CARA More Risky?
TG Therapeutics has a beta of 2.303, which suggesting that the stock is 130.31% more volatile than S&P 500. In comparison Cara Therapeutics has a beta of 0.499, suggesting its less volatile than the S&P 500 by 50.057%.
-
Which is a Better Dividend Stock TGTX or CARA?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Cara Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or CARA?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Cara Therapeutics quarterly revenues of $1.5M. TG Therapeutics's net income of $23.3M is higher than Cara Therapeutics's net income of -$7.7M. Notably, TG Therapeutics's price-to-earnings ratio is 299.21x while Cara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 19.95x versus 3.29x for Cara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics19.95x 299.21x $108.2M $23.3M CARACara Therapeutics3.29x -- $1.5M -$7.7M
-
Which has Higher Returns TGTX or EDIT?
Editas Medicine has a net margin of 21.57% compared to TG Therapeutics's net margin of -148.33%. TG Therapeutics's return on equity of 12.81% beat Editas Medicine's return on equity of -100%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M EDITEditas Medicine-- -$0.55 $134.3M -
What do Analysts Say About TGTX or EDIT?
TG Therapeutics has a consensus price target of $42.83, signalling upside risk potential of 2.25%. On the other hand Editas Medicine has an analysts' consensus of $3.75 which suggests that it could grow by 173.72%. Given that Editas Medicine has higher upside potential than TG Therapeutics, analysts believe Editas Medicine is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 EDITEditas Medicine4 9 0 -
Is TGTX or EDIT More Risky?
TG Therapeutics has a beta of 2.303, which suggesting that the stock is 130.31% more volatile than S&P 500. In comparison Editas Medicine has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.581%.
-
Which is a Better Dividend Stock TGTX or EDIT?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or EDIT?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Editas Medicine quarterly revenues of $30.6M. TG Therapeutics's net income of $23.3M is higher than Editas Medicine's net income of -$45.4M. Notably, TG Therapeutics's price-to-earnings ratio is 299.21x while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 19.95x versus 3.49x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics19.95x 299.21x $108.2M $23.3M EDITEditas Medicine3.49x -- $30.6M -$45.4M
-
Which has Higher Returns TGTX or OCGN?
Ocugen has a net margin of 21.57% compared to TG Therapeutics's net margin of -1816.75%. TG Therapeutics's return on equity of 12.81% beat Ocugen's return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M OCGNOcugen-- -$0.05 $58.3M -
What do Analysts Say About TGTX or OCGN?
TG Therapeutics has a consensus price target of $42.83, signalling upside risk potential of 2.25%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 1071.88%. Given that Ocugen has higher upside potential than TG Therapeutics, analysts believe Ocugen is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 OCGNOcugen2 0 0 -
Is TGTX or OCGN More Risky?
TG Therapeutics has a beta of 2.303, which suggesting that the stock is 130.31% more volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.
-
Which is a Better Dividend Stock TGTX or OCGN?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or OCGN?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Ocugen quarterly revenues of $764K. TG Therapeutics's net income of $23.3M is higher than Ocugen's net income of -$13.9M. Notably, TG Therapeutics's price-to-earnings ratio is 299.21x while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 19.95x versus 38.49x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics19.95x 299.21x $108.2M $23.3M OCGNOcugen38.49x -- $764K -$13.9M
-
Which has Higher Returns TGTX or OCUL?
Ocular Therapeutix has a net margin of 21.57% compared to TG Therapeutics's net margin of -283.27%. TG Therapeutics's return on equity of 12.81% beat Ocular Therapeutix's return on equity of -62.66%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M OCULOcular Therapeutix92.8% -$0.29 $383.8M -
What do Analysts Say About TGTX or OCUL?
TG Therapeutics has a consensus price target of $42.83, signalling upside risk potential of 2.25%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.45 which suggests that it could grow by 134.6%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 OCULOcular Therapeutix5 0 0 -
Is TGTX or OCUL More Risky?
TG Therapeutics has a beta of 2.303, which suggesting that the stock is 130.31% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.685%.
-
Which is a Better Dividend Stock TGTX or OCUL?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or OCUL?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Ocular Therapeutix quarterly revenues of $17.1M. TG Therapeutics's net income of $23.3M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, TG Therapeutics's price-to-earnings ratio is 299.21x while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 19.95x versus 18.47x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics19.95x 299.21x $108.2M $23.3M OCULOcular Therapeutix18.47x -- $17.1M -$48.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
95
EXOD alert for Mar 21
Exodus Movement [EXOD] is up 17.89% over the past day.
Buy
58
SIG alert for Mar 21
Signet Jewelers [SIG] is down 0.64% over the past day.
Sell
43
HQY alert for Mar 21
HealthEquity [HQY] is up 0.28% over the past day.
